Cargando…

Results from ACROCOVID: an international survey on the care of acromegaly during the COVID-19 era

With most global healthcare resources focused on COVID-19, altered resource allocation is disrupting the continuum of care for chronic endocrine conditions, including acromegaly. In order to assess the effects of COVID-19 on care of patients with acromegaly, we conducted an international online surv...

Descripción completa

Detalles Bibliográficos
Autores principales:	Giustina, Andrea, Legg, Ewen, Cesana, Bruno Mario, Frara, Stefano, Mortini, Pietro, Fleseriu, Maria
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer US 2021
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7790473/ https://www.ncbi.nlm.nih.gov/pubmed/33415577 http://dx.doi.org/10.1007/s12020-020-02565-1

Ejemplares similares

Correction: Results from ACROCOVID: an international survey on the care of acromegaly during the COVID-19 era
por: Giustina, Andrea, et al.
Publicado: (2021)

OR32-6 Pre-Surgical GH Levels Predict the Risk of Morphometric Vertebral Fracture, Which Is an Early and Frequent Event in the Natural History of Acromegaly
por: Frara, Stefano, et al.
Publicado: (2019)

MON-LB50 Poor Response to Pre-Surgical Treatment With Somatostatin Receptor Ligands Is Associated With Diabetes Mellitus in Patients With Acromegaly
por: Frara, Stefano, et al.
Publicado: (2020)

COVID-19 and hypopituitarism
por: Frara, Stefano, et al.
Publicado: (2021)

SUN-LB075 Effects of Pegvisomant and Pasireotide LAR on Incidence of Vertebral Fractures in Patients with Acromegaly Resistant to Treatment with First-Line Somatostatin Analogs
por: Chiloiro, Sabrina, et al.
Publicado: (2019)

Results of Gamma Knife Radiosurgery in Acromegaly
por: Franzin, Alberto, et al.
Publicado: (2012)

High Prevalence of Radiological Vertebral Fractures in Patients With TSH-Secreting Pituitary Adenoma
por: Frara, Stefano, et al.
Publicado: (2018)

Glucose metabolism outcomes in acromegaly patients on treatment with pasireotide-LAR or pasireotide-LAR plus Pegvisomant
por: Chiloiro, Sabrina, et al.
Publicado: (2021)

Updates in Diagnosis and Treatment of Acromegaly
por: Zahr, Roula, et al.
Publicado: (2018)

MON-311 Glucose Metabolism in Acromegaly Patients Resistant to First Generation Somatostatin Receptor Ligands Treated with Pegvisomant And/Or Pasireotide Lar
por: Chiloiro, Sabrina, et al.
Publicado: (2020)

Updates in rare and not-so-rare complications of acromegaly: focus on respiratory function and quality of life in acromegaly
por: Langlois, Fabienne, et al.
Publicado: (2020)

Clinical efficacy and safety results for dose escalation of somatostatin receptor ligands in patients with acromegaly: a literature review
por: Fleseriu, Maria
Publicado: (2010)

A Pituitary Society update to acromegaly management guidelines
por: Fleseriu, Maria, et al.
Publicado: (2020)

Pasireotide: a novel treatment for patients with acromegaly
por: Cuevas-Ramos, Daniel, et al.
Publicado: (2016)

The emerging osteo-metabolic phenotype of COVID-19: clinical and pathophysiological aspects
por: di Filippo, Luigi, et al.
Publicado: (2021)

Individualized acromegaly treatment: Is stereotactic radiation therapy changing the paradigm?
por: Liu, Winnie, et al.
Publicado: (2022)

Durable biochemical response and safety with oral octreotide capsules in acromegaly
por: Samson, Susan L, et al.
Publicado: (2022)

Safety and tolerability of pasireotide long-acting release in acromegaly—results from the acromegaly, open-label, multicenter, safety monitoring program for treating patients who have a need to receive medical therapy (ACCESS) study
por: Fleseriu, Maria, et al.
Publicado: (2016)

Hypocalcemia in COVID-19: Prevalence, clinical significance and therapeutic implications
por: di Filippo, Luigi, et al.
Publicado: (2021)

Pituitary tumor centers of excellence for Cushing’s disease
por: Couselo, Marcos, et al.
Publicado: (2022)

The osteo-metabolic phenotype of COVID-19: an update
por: di Filippo, Luigi, et al.
Publicado: (2022)

Meta-Analysis on the Effects of Octreotide on Tumor Mass in Acromegaly
por: Giustina, Andrea, et al.
Publicado: (2012)

The Pharmacological Burden of Comorbidities in Acromegaly
por: Fleseriu, Maria, et al.
Publicado: (2021)

MON-LB53 Prior Injectable Somatostatin Receptor Ligand Dose Does Not Predict Oral Octreotide Response In The Treatment Of Acromegaly: Results From The Phase 3 OPTIMAL Study
por: Nachtigall, Lisa B, et al.
Publicado: (2020)

Vitamin D in the Covid-19 era: a review with recommendations from a G.I.O.S.E.G. expert panel
por: Ulivieri, Fabio Massimo, et al.
Publicado: (2021)

Pegvisomant in acromegaly: an update
por: Giustina, A., et al.
Publicado: (2017)

An evaluation of the Acromegaly Treatment Satisfaction Questionnaire (Acro-TSQ) in adult patients with acromegaly, including correlations with other patient-reported outcome measures: data from two large multicenter international studies
por: Fleseriu, Maria, et al.
Publicado: (2020)

MON-297 Withdrawal from Long-Acting Somatostatin Receptor Ligand Injections in Adult Patients with Acromegaly: Results from the Phase 3, Randomized, Double-Blind, Placebo-Controlled CHIASMA OPTIMAL Study
por: Nachtigall, Lisa B, et al.
Publicado: (2020)

PMON166 Safety Comparison of 40- vs 60-mg/day Doses of Oral Octreotide Capsules for Treatment of Acromegaly in the CHIASMA OPTIMAL Trial
por: Elenkova, Atanaska, et al.
Publicado: (2022)

Maintenance of Acromegaly Control in Patients Switching From Injectable Somatostatin Receptor Ligands to Oral Octreotide
por: Samson, Susan L, et al.
Publicado: (2020)

LBMON178 2nd Year Outcomes Of The Open-label Extension Of Chiasma Optimal, A Phase 3 Study Of Oral Octreotide Capsules In Acromegaly
por: Samson, Susan, et al.
Publicado: (2022)

A Consensus Statement on acromegaly therapeutic outcomes
por: Melmed, Shlomo, et al.
Publicado: (2018)

Oral octreotide capsules for the treatment of acromegaly: comparison of 2 phase 3 trial results
por: Labadzhyan, Artak, et al.
Publicado: (2021)

The Endothelium in Acromegaly
por: Maffei, Pietro, et al.
Publicado: (2019)

Acromegaly at diagnosis in 3173 patients from the Liège Acromegaly Survey (LAS) Database
por: Petrossians, Patrick, et al.
Publicado: (2017)

MON-529 Body Mass Index Predicts Resistance To Active Vitamin D In Patients With Hypoparathyroidism
por: Formenti, Anna Maria, et al.
Publicado: (2019)

COVID-19 and the pituitary
por: Frara, Stefano, et al.
Publicado: (2021)

Low vitamin D levels predict outcomes of COVID-19 in patients with both severe and non-severe disease at hospitalization
por: di Filippo, Luigi, et al.
Publicado: (2023)

A consensus on the diagnosis and treatment of acromegaly complications
por: Melmed, S., et al.
Publicado: (2012)

Correction to: Oral octreotide capsules for the treatment of acromegaly: comparison of 2 phase 3 trial results
por: Labadzhyan, Artak, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_083tpp3esh4nkdcmffa250qd79